00-0000000 0001730463 false 0001730463 2024-05-13 2024-05-13 0001730463 sic:Z8880 2024-05-13 2024-05-13 0001730463 us-gaap:CommonClassAMember 2024-05-13 2024-05-13

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 13, 2024

 

 

Autolus Therapeutics plc

(Exact name of registrant as specified in its Charter)

 

 

 

England and Wales   001-38547   Not applicable

(State or other jurisdiction of

incorporation or organization)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification No.)

The MediaWorks

191 Wood Lane

London W12 7FP

United Kingdom

(Address of principal executive offices) (Zip Code)

(44) 20 3829 6230

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading

Symbol(s)

  

Name of each exchange

on which registered

American Depositary Shares, each representing one ordinary share, nominal value $0.000042 per share   AUTL   The Nasdaq Global Select Market
Ordinary shares, nominal value $0.000042 per share*   *   The Nasdaq Stock Market LLC*

 

*

Not for trading, but only in connection with the listing of the American Depositary Shares on The Nasdaq Global Select Market. The American Depositary Shares represent the right to receive ordinary shares and are being registered under the Securities Act of 1933, as amended, pursuant to a separate Registration Statement on Form F-6. Accordingly, the American Depositary Shares are exempt from the operation of Section 12(a) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 12a-8 thereunder.

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 7.01

Regulation FD Disclosure.

Autolus Therapeutics plc (the “Company”) issued a press release announcing it has rescheduled its first quarter 2024 conference call and webcast. The rescheduled webcast will be held on May 17, 2024 at 8:30 am EDT/1:30 pm BST to discuss the Company’s financial results and provide a general business update. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated by reference herein.

The information contained in this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by reference in such a filing.

 

Item 9.01

Financial Statements and Exhibits

d) Exhibits

 

Exhibit
No.

   

Description of Exhibit

99.1    Press release dated May 13, 2024
104    Cover Page Interactive Data File (embedded within XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

       

 AUTOLUS THERAPEUTICS PLC

Dated: May 13, 2024   By:  

/s/ Christian Itin, Ph.D.

  Name:   Christian Itin, Ph.D.
  Title:   Chief Executive Officer

Exhibit 99.1

 

LOGO

Autolus Therapeutics Announces Delay to its First Quarter 2024 Earnings Release and Conference Call

LONDON, May 13, 2024 — Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it intends to file a Form 12b-25, Notification of Late Filing, with the U.S. Securities and Exchange Commission later this week with regard to its Quarterly Report on Form 10-Q for the quarter ended March 31, 2024 (the “Q1 2024 10-Q”). Form 12b-25 will allow the Company an automatic extension of five additional calendar days to file the Q1 2024 10-Q which is due on May 15, 2024.

In accordance with today’s announcement, the Company is canceling its previously announced earnings release and call scheduled for before U.S. market open on May 14, 2024. The Company expects to file the Q1 2024 10-Q as soon as practicable and no later than the May 20, 2024 deadline in compliance with Rule 12b-25. The Company has rescheduled its first quarter 2024 conference call and webcast to now be held on May 17, 2024 at 8:30 am EDT/1:30 pm BST to discuss the Company’s financial results and provide a general business update. Conference call participants should pre-register using this link to receive the dial-in numbers and a personal PIN, which are required to access the conference call.

A simultaneous audio webcast and replay will be accessible on the events section of Autolus’ website.

Contact:

Olivia Manser

+44 (0) 7780 471568

o.manser@autolus.com

Julia Wilson

+44 (0) 7818 430877

j.wilson@autolus.com

Susan A. Noonan

S.A. Noonan Communications

+1-917-513-5303

susan@sanoonan.com

# # #

 

1

v3.24.1.1.u2
Document and Entity Information
May 13, 2024
Entity Listings [Line Items]  
Document Type 8-K
Document Period End Date May 13, 2024
Entity Registrant Name Autolus Therapeutics plc
Entity Incorporation State Country Code X0
Entity File Number 001-38547
Entity Tax Identification Number 00-0000000
Entity Address Address Line 1 The MediaWorks
Entity Address Address Line 2 191 Wood Lane
Entity Address City Or Town London
Entity Address Postal Zip Code W12 7FP
Entity Address Country GB
City Area Code (44) 20
Local Phone Number 3829 6230
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Entity Central Index Key 0001730463
Amendment Flag false
8880 American Depositary Receipts [Member]  
Entity Listings [Line Items]  
Security 12b Title American Depositary Shares, each representing one ordinary share, nominal value $0.000042 per share
Trading Symbol AUTL
Security Exchange Name NASDAQ
Common Class A [Member]  
Entity Listings [Line Items]  
Security 12b Title Ordinary shares, nominal value $0.000042 per share*
Security Exchange Name NASDAQ
No Trading Symbol Flag true
Autolus Therapeutics (NASDAQ:AUTL)
Graphique Historique de l'Action
De Jan 2025 à Fév 2025 Plus de graphiques de la Bourse Autolus Therapeutics
Autolus Therapeutics (NASDAQ:AUTL)
Graphique Historique de l'Action
De Fév 2024 à Fév 2025 Plus de graphiques de la Bourse Autolus Therapeutics